Are high daily doses of trimethoprim/sulfamethoxazole an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS?
We found a high incidence of ADRs among patients with PJP and AIDS treated with TMP/SMX, and most involved the skin and liver. A daily dose of ≥ 16 mg/kg of TMP/SMX and age 34 years were independent risk factors for ADRs.
The data support a beneficial role for C1-INH in the treatment of ischaemia-reperfusion injuries of skeletal muscles.